SAN
DIEGO, Jan. 6, 2025 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate
presentation at the 43rd Annual J.P. Morgan Healthcare
Conference. The conference will take place January 13-16, 2025, in San Francisco, California.
Details are as follows:
- 43rd Annual J.P. Morgan Healthcare
Conference
Details: Dr. Lian will deliver a corporate
presentation and participate in 1-on-1 meetings
Conference dates: January 13-16,
2025
Presentation Timing: 1:30 – 2:10 p.m.
Pacific on Monday, January 13,
2025
Location: The Westin St. Francis San Francisco on Union Square;
webcast available
A live webcast of the presentation may be accessed via a link on
the Viking Therapeutics website in the Investors & Media
section under Webcasts. Additionally, a replay of the
webcast will be available on the Viking website following the
conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage its
expertise in metabolism to develop innovative therapeutics designed
to improve patients' lives. Viking's clinical programs include
VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1)
and glucose-dependent insulinotropic polypeptide (GIP) receptors
for the potential treatment of various metabolic disorders. Data
from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed
subcutaneously) for metabolic disorders demonstrated an encouraging
safety and tolerability profile as well as positive signs of
clinical benefit. Concurrently, the company is evaluating an oral
formulation of VK2735 in a Phase 1 trial. Viking is also developing
VK2809, a novel, orally available, small molecule selective thyroid
hormone receptor beta agonist for the treatment of lipid and
metabolic disorders. The compound successfully achieved both the
primary and secondary endpoints in a recently completed Phase
2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred
to as metabolic dysfunction associated steatohepatitis, MASH) and
fibrosis. In a Phase 2a trial for the treatment of non-alcoholic
fatty liver disease (NAFLD) and elevated LDL-C, patients who
received VK2809 demonstrated statistically significant reductions
in LDL-C and liver fat content compared with patients who received
placebo. The company's newest program is evaluating a series
of internally developed dual amylin and calcitonin receptor
agonists (or DACRAs) for the treatment of obesity and other
metabolic disorders. In the rare disease space, Viking is
developing VK0214, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the potential
treatment of X-linked adrenoleukodystrophy (X-ALD). In a
Phase 1b clinical trial in patients
with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was
shown to be safe and well-tolerated, while driving significant
reductions in plasma levels of very long-chain fatty acids (VLCFAs)
and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302340335.html
SOURCE Viking Therapeutics, Inc.